Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down – Should You Sell?

Posted by Francis Steltz on Aug 20th, 2026

Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report)’s share price gapped down before the market opened on Thursday . The stock had previously closed at $6.43, but opened at $6.04. Taysha Gene Therapies shares last traded at $6.0750, with a volume of 93,707 shares traded.

Analyst Ratings Changes

A number of research analysts have recently issued reports on TSHA shares. Citigroup reissued an “outperform” rating on shares of Taysha Gene Therapies in a report on Tuesday, June 23rd. Bank of America lifted their price objective on shares of Taysha Gene Therapies from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Monday, June 22nd. The Goldman Sachs Group boosted their price objective on shares of Taysha Gene Therapies from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Needham & Company LLC restated a “buy” rating and set a $12.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, June 30th. Finally, Robert W. Baird raised their target price on shares of Taysha Gene Therapies from $12.00 to $15.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 30th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $12.77.

Get Our Latest Analysis on Taysha Gene Therapies

Taysha Gene Therapies Price Performance

The company has a 50-day simple moving average of $6.16 and a 200-day simple moving average of $5.53. The stock has a market cap of $1.98 billion, a PE ratio of -14.48 and a beta of 1.22. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.76 and a quick ratio of 17.76.

Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). Sell-side analysts anticipate that Taysha Gene Therapies, Inc. will post -0.52 EPS for the current fiscal year.

Insider Activity at Taysha Gene Therapies

In related news, insider Sukumar Nagendran sold 200,000 shares of the firm’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $6.24, for a total value of $1,248,000.00. Following the completion of the sale, the insider owned 936,410 shares in the company, valued at $5,843,198.40. This trade represents a 17.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.48% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in TSHA. Vestal Point Capital LP lifted its position in shares of Taysha Gene Therapies by 150.0% during the 4th quarter. Vestal Point Capital LP now owns 13,750,000 shares of the company’s stock valued at $75,625,000 after acquiring an additional 8,250,000 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of Taysha Gene Therapies by 2.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 13,692,739 shares of the company’s stock worth $75,310,000 after acquiring an additional 309,031 shares during the period. Vanguard Group Inc. grew its holdings in shares of Taysha Gene Therapies by 3.3% in the 4th quarter. Vanguard Group Inc. now owns 13,267,805 shares of the company’s stock worth $72,973,000 after acquiring an additional 418,192 shares during the period. Octagon Capital Advisors LP increased its stake in Taysha Gene Therapies by 17.7% in the 2nd quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company’s stock valued at $29,089,000 after purchasing an additional 1,892,500 shares in the last quarter. Finally, State Street Corp increased its stake in Taysha Gene Therapies by 49.1% in the 4th quarter. State Street Corp now owns 10,790,084 shares of the company’s stock valued at $59,345,000 after purchasing an additional 3,553,619 shares in the last quarter. 77.70% of the stock is owned by hedge funds and other institutional investors.

About Taysha Gene Therapies

(Get Free Report)

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.